Payton Engdahl

Payton Engdahl asked about the pharma budget spending environment, specifically if GoodRx has observed any impact on the size, duration, or ramp time of new Pharma Direct programs due to pharma clients increasingly releasing budgets in smaller, more phased increments.

Answer

Wendy Barnes (CEO, GoodRx) noted a contrary trend where more spending has been pulled forward in their sales cycle. Laura Jensen (Chief Commercial Officer and President of Pharma Direct, GoodRx) confirmed this, stating that some key partners are booking earlier in the year and that pharmaceutical manufacturer budgets, especially on the direct-to-consumer side, remain healthy. Wendy Barnes further added that Pharma Direct bookings as a percentage of their overall plan are up relative to the same point last year.

Payton Engdahl asked about the pharmaceutical budget spending environment, specifically if GoodRx has observed any impact on the size, duration, or ramp time of new Pharma Direct programs, given trends of budgets being released in smaller, more phased increments.

Answer

Wendy Barnes, Chief Executive Officer, noted a contrary observation, with more spending being pulled forward in their sales cycle. Laura Jensen, Chief Commercial Officer and President of Pharma Direct, confirmed this trend, stating that partners are booking earlier in the year and that pharmaceutical manufacturer budgets for direct-to-consumer programs remain healthy. Wendy added that Pharma Direct bookings as a percentage of the overall plan are up year-over-year.